The global androgenic alopecia drug market is anticipated to grow at a significant CAGR during the forecast period. The growing prevalence of hair loss, technological advancements in alopecia treatment, and the rise in prevalence of chronic diseases that are associated with hair loss are some of the major factors driving the market. According to data published by the American Hair Loss Association, it was stated that over 95.0% of hair loss in men is caused due to androgenic alopecia. Similarly, data published by the International Society of Hair Restoration Surgery estimated that nearly 40.0% of men encounter some degree of hair loss by 35 years of age, 65.0% at 60 years, 70.0% at 80 years, and 80.0% at the age of 85. Thus, this factor is propelling the global androgenic alopecia drug market growth.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/androgenic-alopecia-drug-market
Apart from the general misconception that alopecia affects males, females too encounter this condition on a wide scale. According to the American Academy of Dermatology Association (AAD), about 50 million men and 30 million women were estimated to be affected by some form of alopecia in the US in 2018. According to data published by the Journal of Clinical and Diagnostic Research (JCDR), around 60% of the population has hair thinning problems and pattern hair loss is the most common form of hair loss in both males and females. Moreover, around 2.0% of the population all over the globe is at risk of developing androgenic alopecia in their lifetime, irrespective of gender. This, in turn, is driving the demand for androgenic alopecia drug market.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Type
o By End-User
- Regions covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape: Allergan plc, Cipla Ltd., and Dr. Reddy’s Laboratories, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Androgenic Alopecia Drug Market Report by Segment
By Type
- RK-023
- RCH-01
- Refagro
- SM-04554
- HYG-440
- Others
By End-User
- Clinic
- Hospital
- Homecare Settings
A full report of Androgenic Alopecia Drug Market is available at: https://www.omrglobal.com/industry-reports/androgenic-alopecia-drug-market
Androgenic Alopecia Drug Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Allergan plc
- Cipla Ltd.
- Reddy’s Laboratories
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
